EUVIMEDEUVIMED entdecken
Multizentrische Studie

Impact of Immunotherapy Addition on Dose Density and Clinical Outcomes of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Retrospective, Real-world Study From Multiple Centers in London, UK

Rooman Javed, Mesel Veli, Karen De Souza, Petros Fessas, Lucy Millar, Doreen Koske, Roshni Dasgupta, Bosire Oroko, Ruqayah Muhammad, Juned Islam, Sulaman Rai, Amna Sheri und 4 weitere

Clinical Breast Cancer · 2026

DOI: 10.1016/j.clbc.2026.07.018 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Breast Cancer, 2026. Verfasst von Rooman Javed und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University College London Hospitals NHS Foundation Trust (UCLH), London, United Kingdom. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Triple Negative Breast Neoplasms, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Neoadjuvant chemotherapy (NACT) combined with pembrolizumab is now standard care for early-stage, triple-negative breast cancer (TNBC), based on KEYNOTE-522 demonstrating improved pathological complete response (pCR), event-free survival, and overall survival. However, the real-world impact of treatment modifications due to toxicity remains unclear. We evaluated clinical outcomes and treatment delivery in routine practice. MATERIALS AND METHODS: This multicenter retrospective study included patients with stage II to III TNBC treated with NACT plus pembrolizumab across 5 UK centers (May 2022-June 2025). Data on immune-related adverse events (irAES), corticosteroid use, immunotherapy omissions, chemotherapy dose reductions and recurrence were collected. pCR rates were compared according to treatment modifications. RESULTS: One hundred patients were analyzed (median age 50 years; 54% node-positive). Overall pCR rate was 54.0%, with no significant difference by pembrolizumab omissions (0: 55.0%; 1-3: 55.6%; ≥ 4: 46.2%; P = .83) or corticosteroid use (48.3% vs. 56.3%; P = .61). Grade ≥ 3 toxicities occurred in 37%, and 29% required corticosteroids, most commonly between cycles 2 to 4. Pembrolizumab omissions occurred in 40%, chemotherapy dose reductions in 57%; 23% did not complete planned chemotherapy. Fourteen recurrences were observed (median 11 months), predominantly in baseline node-positive disease; 4 occurred despite pCR. CONCLUSIONS: In real-world practice, pembrolizumab-based NACT is associated with frequent treatment modification, yet pCR rates remain comparable to trial data. Early recurrences-often in node-positive patients and occasionally despite pCR-highlight the need for improved risk stratification, optimized adjuvant strategies, and proactive toxicity management to ameliorate long-term outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyTriple Negative Breast NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleRetrospective StudiesMiddle AgedPathologic Complete ResponseAdultLondonAgedNeoplasm Recurrence, LocalTreatment OutcomeChemotherapy, Adjuvant

Stichwörter der Autor:innen

Early recurrenceImmune relatedPathological complete responsePembrolizumabTreatment modifications

Substanzen

Antibodies, Monoclonal, Humanizedpembrolizumab

Autor:innen und Institutionen

  • Department of Oncology, University College London Hospitals NHS Foundation Trust (UCLH), London, United Kingdom.
  • Department of Oncology, University College London Hospitals NHS Foundation Trust (UCLH), London, United Kingdom; Department of Oncology, Whittington Health NHS Trust, London, United Kingdom.
  • Department of Oncology, Royal Free Hospital (RFH), London, United Kingdom.
  • Department of Oncology, North Middlesex University Hospital NHS Trust, London, United Kingdom.
  • Department of Oncology, Princess Alexandra Hospital NHS Trust (PAH), London, United Kingdom.
  • Department of Oncology, Whittington Health NHS Trust, London, United Kingdom.

Zitieren

APA

Javed, R., Veli, M., De Souza, K., Fessas, P., Millar, L., Koske, D., Dasgupta, R., Oroko, B., Muhammad, R., Islam, J., Rai, S., Sheri, A., Konstantis, A., Raja, F., Ottaviani, D., & Papadimitraki, E. (2026). Impact of Immunotherapy Addition on Dose Density and Clinical Outcomes of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Retrospective, Real-world Study From Multiple Centers in London, UK. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2026.07.018

Vancouver

Javed R, Veli M, De Souza K, Fessas P, Millar L, Koske D, et al. Impact of Immunotherapy Addition on Dose Density and Clinical Outcomes of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Retrospective, Real-world Study From Multiple Centers in London, UK. Clinical Breast Cancer. 2026. doi:10.1016/j.clbc.2026.07.018

BibTeX
@article{Javed2026,
  author = {Javed, Rooman and Veli, Mesel and De Souza, Karen and Fessas, Petros and Millar, Lucy and Koske, Doreen and Dasgupta, Roshni and Oroko, Bosire and Muhammad, Ruqayah and Islam, Juned and Rai, Sulaman and Sheri, Amna and Konstantis, Apostolos and Raja, Fharat and Ottaviani, Diego and Papadimitraki, Elisavet},
  title = {Impact of Immunotherapy Addition on Dose Density and Clinical Outcomes of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Retrospective, Real-world Study From Multiple Centers in London, UK},
  journal = {Clinical Breast Cancer},
  year = {2026},
  doi = {10.1016/j.clbc.2026.07.018}
}
Kostenlos starten →